# Chuanxin Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chuanxin-biomedical

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.themediumtx.com
- Latest round: Angel (Jan 1, 2022)
- Investors on record: 4

## About

Established in 2021 and based in Suzhou, China, Chuanxin Biomedical operates as an RNA drug research and development service provider, dedicated to the commercial development of RNA drugs. The founder, Jianxin Chen, is the co-founder of Acuitas Therapeutics Inc. In May 2021, the company received a license from Acuitas to use its nanolipid particle delivery technology. In June 2023, Chuanxin Biomedical raised CNY 150 million in strategic investment from new investor Changchun Bcht Biotechnology Co.

Through LNP delivery technology, the company has established an mRNA drug development and scale up production system, and also developed novel infectious disease and tumor mRNA vaccines. Chuanxin Biomedical has also developed four core technology platforms, including a nucleic acid technology innovation platform, a delivery technology development platform, an LNP manufacturing platform and, a bioevaluation platform.

## Funding rounds

- Angel, Jan 1, 2022 — Huagai Capital, YuanBio Venture, Hongtai Aplus, Jianyin Medical Grouth Fund
- Angel, Jun 1, 2021 — Huagai Capital, YuanBio Venture

## Investors

- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Angel
- Jianyin Medical Grouth Fund — Angel